Showing results (21-30 of 245) with videos related to
Sort By:
Pageof 25
Drugs|November 27, 2013
Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical useGiuseppe Aprile, Marta Bonotto, Elena Ongaro, et al.Clinical & Experimental Metastasis|September 8, 2015
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategyCaterina Fontanella, Valentina Fanotto, Karim Rihawi, et al.Oncotargets and Therapy|December 2, 2020
Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex MutationFrancesca Simionato, Lorenzo Calvetti, Marco Cosci, et al.Tumori|May 9, 2015
Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature reviewMarianna Macerelli, Micol Mazzer, Luisa Foltran, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 7, 2022
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancerJacopo Giuliani, Beatrice Mantoan, Lucrezia Ferrario, et al.Oncology|May 13, 2022
Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic CancerMartina Catalano, Monica Ramello, Raffaele Conca, et al.Annals of Translational Medicine|January 9, 2015
Clinical advances in the development of novel VEGFR2 inhibitorsCaterina Fontanella, Elena Ongaro, Silvia Bolzonello, et al.BMC Health Services Research|February 11, 2014
Drug waste minimization as an effective strategy of cost-containment in oncologyGianpiero Fasola, Giuseppe Aprile, Luisa Marini, et al.Journal of Clinical Medicine|April 30, 2021
Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the PancreasMartina Catalano, Giuseppe Aprile, Monica Ramello, et al.Cancer Chemotherapy and Pharmacology|October 27, 2012
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe studyGerardo Rosati, Antonio Avallone, Giuseppe Aprile, et al.Pageof 25